Despite progressive improvements in the management of patients with coronavirus disease
2019 (COVID-19), individuals with end-stage kidney disease (ESKD) are still at high risk of …

The Omicron variant, which has become the dominant strain of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) worldwide, brings new challenges to preventing and …

Solid organ transplant (SOT) recipients are at high risk for severe disease with severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Emerging variants of concern …

Data regarding coronavirus disease 2019 (COVID-19) outcomes in solid organ transplant
recipients (SOTr) across severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Background Nirmatrelvir/ritonavir has been shown to reduce the risk of coronavirus disease
2019 (COVID-19)–related complications in patients at high risk for severe COVID-19 …

Infection from the Omicron variant of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) seems to be less severe in general population in comparison with the …

Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in... : Transplantation
Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant …

Abstract Although the mRNA SARS-CoV-2 vaccine has improved the mortality rate in the
general population, its efficacy against rapidly mutating virus strains, especially in kidney …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron strain was first
detected in South Africa in November 2021. Although clinical responses to SARS-CoV-2 …

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an
important prophylactic measure in kidney transplant recipients (KTRs), but the immune …